BioNTech SE (LON:0A3M)
London · Delayed Price · Currency is GBP · Price in USD 103.50
-0.89 (-0.85%)
At close: Sep 7, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
292.28K GBP
Profits / Employee
-186.00K GBP
Market Cap
18.29B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BT Group | 77,200 |
| International Consolidated Airlines Group | 76,581 |
| Aviva | 39,359 |
| Coca-Cola HBC AG | 33,500 |
| NEXT plc | 31,589 |
| Experian | 25,200 |
| Imperial Brands | 25,100 |
| Prudential | 15,338 |
BioNTech SE News
- 18 hours ago - BioNTech downgraded to Market Perform from Outperform at BMO Capital - TheFly
- 8 days ago - BioNTech price target lowered to $136 from $142 at Canaccord - TheFly
- 11 days ago - BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why - TipRanks
- 11 days ago - Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital - TheFly
- 11 days ago - mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley - TheFly
- 11 days ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 11 days ago - BioNTech drops 9% after ending Phase 2 colorectal cancer trial - TheFly
- 11 days ago - BioNTech to terminate Phase 2 monotherapy trial of cevumeran - TheFly